Review



pan-tgfβ neutralizing antibodies clone 1d11  (Genzyme)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Genzyme pan-tgfβ neutralizing antibodies clone 1d11
    A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, <t>TGFβ,</t> IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).
    Pan Tgfβ Neutralizing Antibodies Clone 1d11, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pan-tgf%CE%B2+neutralizing+antibodies+clone+1d11/pmc04868699-156-24-31?v=Genzyme
    Average 90 stars, based on 1 article reviews
    pan-tgfβ neutralizing antibodies clone 1d11 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs"

    Article Title: Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs

    Journal: Oncotarget

    doi: 10.18632/oncotarget.6562

    A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, TGFβ, IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).
    Figure Legend Snippet: A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, TGFβ, IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).

    Techniques Used: Flow Cytometry, Expressing, Isolation, Concentration Assay, Derivative Assay

    A. Representative FACS plots and B. CD4 + /CD25 + /Foxp3 + Tregs generated ex vivo by syngeneic alveolar macrophages (AM) from naive CD4+ − T cells (T cell: AM ratio is 2:1) alone or after treatment with antibodies to TGFβ (10 ug/ml, 1D11) or IL-10 (10 ug/ml, JES5-2A5), or in presence of an inhibitor of retinoic acid synthesis (DEAB, 15 uM). Alveolar macrophages were collected from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). Prior to co-culture CD4+ naive T cells were activated through T cell receptors (TCR stimul) using CD3/CD28 antibody cocktail. Analysis of CD4+CD25+Foxp3+ Tregs was performed in triplicate after 3 days of co-culture, *p < 0.05. C–D. mRNA expression of RALDH1 and RALDH2 by alveolar macrophages from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). *p < 0.05.
    Figure Legend Snippet: A. Representative FACS plots and B. CD4 + /CD25 + /Foxp3 + Tregs generated ex vivo by syngeneic alveolar macrophages (AM) from naive CD4+ − T cells (T cell: AM ratio is 2:1) alone or after treatment with antibodies to TGFβ (10 ug/ml, 1D11) or IL-10 (10 ug/ml, JES5-2A5), or in presence of an inhibitor of retinoic acid synthesis (DEAB, 15 uM). Alveolar macrophages were collected from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). Prior to co-culture CD4+ naive T cells were activated through T cell receptors (TCR stimul) using CD3/CD28 antibody cocktail. Analysis of CD4+CD25+Foxp3+ Tregs was performed in triplicate after 3 days of co-culture, *p < 0.05. C–D. mRNA expression of RALDH1 and RALDH2 by alveolar macrophages from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). *p < 0.05.

    Techniques Used: Generated, Ex Vivo, Co-Culture Assay, Expressing



    Similar Products

    pan-tgfβ neutralizing antibodies clone 1d11  (Genzyme)
    90
    Genzyme pan-tgfβ neutralizing antibodies clone 1d11
    A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, <t>TGFβ,</t> IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).
    Pan Tgfβ Neutralizing Antibodies Clone 1d11, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pan-tgf%CE%B2+neutralizing+antibodies+clone+1d11/pmc04868699-156-24-31?v=Genzyme
    Average 90 stars, based on 1 article reviews
    pan-tgfβ neutralizing antibodies clone 1d11 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, TGFβ, IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).

    Journal: Oncotarget

    Article Title: Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs

    doi: 10.18632/oncotarget.6562

    Figure Lengend Snippet: A. Number of CD45+/CD68+ macrophages identified by flow cytometry in lungs of IKTA mice at baseline (week 0) or after dox treatment (0.1 g/L, n = 3-6 mice per group per time point, *p < 0.05 compared to the baseline). B. Representative photomicrograph of alveolar macrophages collected from IKTA after 3 weeks of dox treatment. C–I. mRNA expression for M1 markers (TNFα, CCL3) and M2 markers (Ym1, Fizz1, Arginase-1, TGFβ, IL-10) by alveolar macrophages isolated from WT and IKTA mice after 3 weeks of continuous treatment with dox. *p < 0.05. J. Total TGFβ concentration in BAL and K. IL-10 concentration in whole lung homogenates collected from WT and IKTA mice after 3 weeks of dox treatment. ND - not detected, *p < 0.05. L. CD11b + lung macrophages (MΦ) collected from WT and IKTA mice after 3 weeks of dox treatment reduce proliferation of CD4 + T cells stimulated by allogeneic bone marrow-derived dendritic cells (DC).

    Article Snippet: To investigate contribution of TGFβ, IL-10 and retinoic acids in generation of Foxp3+ Tregs by alveolar macrophages, cells were co-cultured in the presence of pan-TGFβ neutralizing antibodies (10 μg/ml, clone 1D11, Genzyme Corp) [ ], anti-IL-10 antibodies (10 ug/ml, clone JES5-2A5, Biolegend) or IgG1 isotype control antibodies (Biolegend, San Diego, CA, USA) or a RALDH inhibitor, 4-(diethylamino)benzaldehyde (DEAB; 15 μM, Sigma-Aldrich) [ ], added to culture media at day 0.

    Techniques: Flow Cytometry, Expressing, Isolation, Concentration Assay, Derivative Assay

    A. Representative FACS plots and B. CD4 + /CD25 + /Foxp3 + Tregs generated ex vivo by syngeneic alveolar macrophages (AM) from naive CD4+ − T cells (T cell: AM ratio is 2:1) alone or after treatment with antibodies to TGFβ (10 ug/ml, 1D11) or IL-10 (10 ug/ml, JES5-2A5), or in presence of an inhibitor of retinoic acid synthesis (DEAB, 15 uM). Alveolar macrophages were collected from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). Prior to co-culture CD4+ naive T cells were activated through T cell receptors (TCR stimul) using CD3/CD28 antibody cocktail. Analysis of CD4+CD25+Foxp3+ Tregs was performed in triplicate after 3 days of co-culture, *p < 0.05. C–D. mRNA expression of RALDH1 and RALDH2 by alveolar macrophages from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). *p < 0.05.

    Journal: Oncotarget

    Article Title: Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs

    doi: 10.18632/oncotarget.6562

    Figure Lengend Snippet: A. Representative FACS plots and B. CD4 + /CD25 + /Foxp3 + Tregs generated ex vivo by syngeneic alveolar macrophages (AM) from naive CD4+ − T cells (T cell: AM ratio is 2:1) alone or after treatment with antibodies to TGFβ (10 ug/ml, 1D11) or IL-10 (10 ug/ml, JES5-2A5), or in presence of an inhibitor of retinoic acid synthesis (DEAB, 15 uM). Alveolar macrophages were collected from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). Prior to co-culture CD4+ naive T cells were activated through T cell receptors (TCR stimul) using CD3/CD28 antibody cocktail. Analysis of CD4+CD25+Foxp3+ Tregs was performed in triplicate after 3 days of co-culture, *p < 0.05. C–D. mRNA expression of RALDH1 and RALDH2 by alveolar macrophages from WT and IKTA mice after 3 weeks of continuous treatment with dox (0.1g/L). *p < 0.05.

    Article Snippet: To investigate contribution of TGFβ, IL-10 and retinoic acids in generation of Foxp3+ Tregs by alveolar macrophages, cells were co-cultured in the presence of pan-TGFβ neutralizing antibodies (10 μg/ml, clone 1D11, Genzyme Corp) [ ], anti-IL-10 antibodies (10 ug/ml, clone JES5-2A5, Biolegend) or IgG1 isotype control antibodies (Biolegend, San Diego, CA, USA) or a RALDH inhibitor, 4-(diethylamino)benzaldehyde (DEAB; 15 μM, Sigma-Aldrich) [ ], added to culture media at day 0.

    Techniques: Generated, Ex Vivo, Co-Culture Assay, Expressing